G2G Bio signs Celltrion MOU on subcutaneous antibody formulation platform

The partnership will test G2G Bio’s InnoBioLAMP technology with Celltrion antibody materials as the company broadens beyond long-acting drug delivery systems into biologics formulation development.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.